IPHA (Innate Pharma) Growth Rank: 6 (As of Jul. 15, 2026) — 50% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IPHA Innate Pharma SA IPHA
41 GF Score
Price $1.80
GF Value $0.16
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Innate Pharma Growth Rank?

Innate Pharma IPHA +0.56% 41 Growth Rank is 6 as of Jul. 15, 2026, which is 50% above its 10-year median of 4.00. GuruFocus rates IPHA with a GF Score™ of 41/100 and a GF Value™ of $0.16 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Innate Pharma has the Growth Rank of 6.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

IPHA vs VRTX, REGN, ALNY: Growth Rank Comparison

For the Biotechnology subindustry, Innate Pharma's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innate Pharma Growth Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innate Pharma's Growth Rank distribution charts can be found below:

* The bar in red indicates where Innate Pharma's Growth Rank falls into.


IPHA
41GF Score
Innate Pharma SA IPHA
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 6 mean?
Innate Pharma (IPHA) has a Growth Rank of 6 as of Jul. 15, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Innate Pharma and its competitors. This is 50% above median its historical median of 4.00. Over the past decade, Innate Pharma's Growth Rank has ranged from 1.00 to 10.00.
Is Innate Pharma's Growth Rank too high?
Innate Pharma's current Growth Rank of 6 is 50% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Innate Pharma has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Innate Pharma's Growth Rank compare to VRTX and REGN?
Innate Pharma's Growth Rank of 6 can be compared against companies in the Biotechnology industry. Historically, Innate Pharma's own Growth Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Biotechnology company?
A good Growth Rank depends on the Biotechnology industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Innate Pharma and its competitors. Innate Pharma's current Growth Rank is 6, which is 50% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innate Pharma stock overvalued right now?
Based on GuruFocus' analysis, Innate Pharma (IPHA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.16, compared to a current price of $1.80 — trading 1025% above its estimated fair value. The current Growth Rank is 6, which is 50% above median its 10-year median of 4.00. Innate Pharma's overall GF Score™ is 41/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Innate Pharma (IPHA), the current Growth Rank is 6 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Innate Pharma (IPHA) Overvalued in 2026?

Based on GuruFocus' analysis, Innate Pharma stock appears to be overvalued. The current stock price of $1.80 is trading 1025% above its estimated GF Value™ of $0.16. GuruFocus considers Innate Pharma to be Significantly Overvalued.

Key valuation signals for IPHA:

  • Growth Rank: 6 (50% above median its 10-year median of 4.00)
  • GF Value™: $0.16 vs. price of $1.80 (1025% above fair value)
  • GF Score™: 41/100 with 7 warning signs

No single metric tells the full story. See the IPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Innate Pharma Business Description

Address 117, Avenue de Luminy, Marseille, FRA, 13009
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
41GF Score

Get the complete analysis for IPHA

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.80
Price
$0.16
GF Value